Utility of the p53 mutant protein in patients with low-risk myelodysplastic syndrome
AUTOR(ES)
Yao, David C., Lima, Marcos de
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2014-06
RESUMO
Documentos Relacionados
- Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome
- Scientific comment on tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome
- Improving care of patients with low-risk differentiated thyroid carcinoma
- Amphotericin B-related nephrotoxicity in low-risk patients
- Are urban safety-net hospitals losing low-risk Medicaid maternity patients?